Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma
- 1 November 2011
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 29 (11) , 977-988
Abstract
Background: Angiogenesis inhibitor agents have been shown to be effective in increasing progression-free survival (PFS) in patients with renal cell carcinoma (RCC); however, these treatments have...Keywords
This publication has 28 references indexed in Scilit:
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall SurvivalJournal of Clinical Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Benefits, Risk, and Uncertainty: Preferences of Antiretroviral-Naïve African Americans for HIV TreatmentsAIDS Patient Care and STDs, 2009
- Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experimentHaemophilia, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experimentHaemophilia, 2005
- The Importance of Utility Balance in Efficient Choice DesignsJournal of Marketing Research, 1996